PRE-dialysis survey on anaemia management.
BACKGROUND
The PRE-dialysis survey on anaemia management (PRESAM) was designed to assess the care given to pre-dialysis patients in the 12 months before haemodialysis or peritoneal dialysis, with emphasis on anaemia management.


METHODS
For this epidemiological study, a retrospective chart review was conducted for patients who started haemodialysis or peritoneal dialysis between 1 August, 1999 and 6 April, 2000. All adult patients who entered one of the 779 participating centres in 21 European countries, Israel or South Africa were included, except for patients who underwent dialysis only during an acute episode. In addition to demographic characteristics, the study examined the prevalence of anaemia, anaemia management including the use of iron supplementation and epoetin, source of referral to the dialysis centre, comorbidities and major clinical events.


RESULTS
A total of 4333 new dialysis patients were included in the survey. At the first visit to the dialysis centre, 68% of the patients had a haemoglobin (Hb) concentration < or = 11.0 g/dl; Hb concentration was positively correlated with creatinine clearance rate (r = 0.43, P < 0.01). Patients who received epoetin had a mean Hb concentration of 8.8 g/dl at the start of epoetin treatment, and 96% of these patients had an Hb concentration < or = 11.0 g/dl. Only 26.5% of the patients received epoetin before dialysis. The length of time under the care of a nephrologist was associated with meeting the European Best Practice Guidelines (EBPG) target Hb concentration, as well as receiving epoetin.


CONCLUSIONS
Few pre-dialysis patients met the EBPG target for Hb concentration, despite regular nephrology care.
Valderrábano
Fernando
F
Servicio Nefrología, Hospital Gregorio Marañon, Madrid, Spain.
Hörl
Walter H
WH
Macdougall
Iain C
IC
Rossert
Jérôme
J
Rutkowski
Boleslaw
B
Wauters
Jean-Pierre
JP
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D006306:Health Surveys; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000097:blood / Q000378:metabolism; D007557:Israel; D008297:Male; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D006435:Renal Dialysis; D012189:Retrospective Studies; D013019:South Africa; D013997:Time Factors
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa; D007501:Iron